ClinicalTrials.gg

Non-alcoholic Fatty Liver Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,618 studies for Non-alcoholic Fatty Liver Disease across more than 10 countries. 322 are recruiting or about to start. 1,254 of them are mainly about Non-alcoholic Fatty Liver Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18.

ClinicalTrials.gov finds 1,709 studies for Non-alcoholic Fatty Liver Disease. How that becomes 1,617 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Non-alcoholic Fatty Liver Disease, and those it files under no condition that list Non-alcoholic Fatty Liver Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 1,709Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −5List Non-alcoholic Fatty Liver Disease as a condition, but the registry did not file them under itMost often written as “Non-alcoholic Fatty Liver Disease NAFLD” (2), “NAFLD - Non-Alcoholic Fatty Liver Disease” (1), and “Non-alcoholic Fatty Liver Diseases” (1). The registry filed them under other conditions only, most often Fatty Liver (2) and Diabetes Mellitus, Type 2 (1).
  3. −89Match it another way54 name it in the title, 2 in a keyword, and 33 by a synonym or other text the search reads.
  4. 1,615Counted here and found by its search14 of them list Non-alcoholic Fatty Liver Disease in their own words; the registry filed them under no condition.
  5. +2
    Counted here, but its search does not find them
  6. 1,617The count on this page

Status

Completed
847
Status unknown
220
Recruiting
219
Terminated
94
Active, not recruiting
88
Not yet recruiting
82

Phase

Phase 2
351
Phase 1
181
Phase 3
92
Phase 4
80
Early Phase 1
15

Where

United States
547
China
143
United Kingdom
122
France
104
Italy
99
Canada
91

Who develops what

Add Non-alcoholic Fatty Liver Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 15 programs from 12 companies, 15 with this as their studies’ main aim; 6 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Eli Lilly, Regeneron Pharmaceuticals and China Resources Pharmaceutical Group here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TirzepatideRecent, limited
Evidence
  • NCT07527910 · Regeneron Pharmaceuticals · Phase 2 · live · background · “Tirzepatide” · registered Apr 2026
Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2022)EU: Eli Lilly and Company (EMA 2022)11 study
empagliflozinRecent, limited
Evidence
  • NCT05232071 · Inventiva Pharma · Phase 2 · background · “Empagliflozin” · registered Jan 2022
Boehringer Ingelheim70% of its industry studiesEU: Boehringer Ingelheim (EMA 2014)11 study
SemaglutideRecent, limited
Evidence
  • NCT05877547 · Merck & Co., Inc · Phase 2 · comparator · “Semaglutide” · registered May 2023
  • NCT04944992 · Merck & Co., Inc · Phase 2 · comparator · “Semaglutide 1.34 mg/mL” · registered Jun 2021
Novo Nordisk A/S89% of its industry studiesUS: Novo Nordisk A/S (FDA 2019)EU: Novo Nordisk A/S (EMA 2018)11 study

2 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
efimosfermin alfa☆ Track2 live phase-3 studies: NCT07221188, NCT07221227GlaxoSmithKline
DR10624☆ Track1 live phase-3 study: NCT07693777Huadong Medicine Co., Ltd.
ALN-CIDEB☆ Track1 live phase-3 study: NCT07854782Regeneron Pharmaceuticals
HSK31679☆ Track1 live phase-3 study: NCT07581951Haisco Pharmaceutical Group Co., Ltd.
TirzepatideApproved: US 2022 · EU 2022☆ Track1 live phase-3 study: NCT07165028Eli Lilly and Company

The 5 in phase 3 with the nearest primary completion, of 15 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 14 Feb 2027 est.tesamorelin · Hudson Biotech · Phase 2 main aimNCT07481734 Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease — primary endpoint: Change from baseline in hepatic fat fraction by MRI-PDFF (percentage points) · 120 enrolled
  • 10 Aug 2027 est.ALN-PNP · Regeneron Pharmaceuticals · Phase 2 registry mapping onlyNCT05648214 A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) · 172 enrolled
  • 17 Aug 2027 est.ALN-CIDEB · Regeneron Pharmaceuticals · Phase 2 registry mapping onlyNCT06836609 A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — primary endpoint: Incidence of Treatment-Emergent Adverse Events (TEAEs) · 118 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Non-alcoholic Fatty Liver Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 6 open · SGLT2 inhibitors 5 open · Statins 3 open · DPP-4 inhibitors 8 · Androgens 4

Coming up

90studies finish main data collection within a year5 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger. 27 (12%) take children under 18. 8 (4%) are for women only and 2 (1%) for men only; 55 (25%) take healthy volunteers.

Recruiting studies that take each age, of 219
AgeWomenMen
1021 (10%)21 (10%)
18180 (82%)178 (81%)
30184 (84%)181 (83%)
40194 (89%)190 (87%)
50191 (87%)190 (87%)
65177 (81%)176 (80%)
75137 (63%)135 (62%)
8576 (35%)75 (34%)

Across all 1,618 studies, recruiting or not: 63% stop at 75 or younger and 33% at 65; 11% take children; 2% are for women only and 3% for men only; 25% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Non-alcoholic Fatty Liver Disease studies take

Of 185 phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 110 mo5–21 · 125 studies10 mo4–16 · 104 studies—
Phase 1/223 mo16–36 · 21 studies——
Phase 226 mo16–36 · 185 studies22 mo15–30 · 132 studies40 mo25–56 · 53 studies
Phase 336 mo25–61 · 34 studies——
Phase 425 mo13–46 · 44 studies—25 mo13–46 · 41 studies
Interventional, no phase25 mo12–48 · 384 studies19 mo10–27 · 28 studies26 mo12–51 · 356 studies
Observational49 mo24–124 · 171 studies—55 mo29–125 · 160 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,618. Browse all 1,618 → or search them.